NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

Most-Downgraded Stocks

$107.69

-1.60 (-1.46 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$107.64

Now: $107.69▼

$110.52

50-Day Range

$90.21

MA: $98.52▼

$112.32

52-Week Range

$72.14

Now: $107.69▼

$136.26

Volume610,734 shs

Average Volume795,578 shs

Market Capitalization$10.06 billion

P/E Ratio115.80

Dividend YieldN/A

Beta1.01

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL Â- Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

2.09 out of 5 stars

Medical Sector

35th out of 1,558 stocks

Biological Products, Except Diagnostic Industry

4th out of 143 stocks

3.3 Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 11 buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $126.53, Neurocrine Biosciences has a forecasted upside of 17.5% from its current price of $107.69.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.6 Community Rank

Outperform Votes
Neurocrine Biosciences has received 885 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Neurocrine Biosciences has received 347 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Neurocrine Biosciences has received 71.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote “Outperform” if you believe NBIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,923,853.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
95.25% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 191.94% in the coming year, from $1.24 to $3.62 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 115.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.54.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 115.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.09.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 15.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:NBIX

Previous Symbol

CUSIP64125C10

CIK914475

Webwww.neurocrine.com

Phone858-617-7600

Employees825

Debt

Debt-to-Equity RatioN/A

Current Ratio1.89

Quick Ratio1.86

Price-To-Earnings

Trailing P/E Ratio115.80

Forward P/E Ratio86.85

P/E GrowthN/A

Sales & Book Value

Annual Sales$788.10 million

Price / Sales12.77

Cash Flow$0.68 per share

Price / Cash Flow158.60

Book Value$6.92 per share

Price / Book15.56

Profitability

EPS (Most Recent Fiscal Year)$0.39

Net Income$37.01 million

Net Margins8.96%

Return on Equity18.18%

Return on Assets9.50%

Miscellaneous

Outstanding Shares93,430,000

Market Cap$10.06 billion

Next Earnings Date2/2/2021 (Estimated)

OptionableOptionable

$107.69

-1.60 (-1.46 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by Coronavirus?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIX shares have increased by 25.4% and is now trading at $107.69.
View which stocks have been most impacted by COVID-19.

Is Neurocrine Biosciences a buy right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neurocrine Biosciences?

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Saturday, November, 14th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.73. The business earned $258.80 million during the quarter, compared to analyst estimates of $282.59 million. Neurocrine Biosciences had a net margin of 8.96% and a return on equity of 18.18%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share.
View Neurocrine Biosciences' earnings history.

What price target have analysts set for NBIX?

19 brokers have issued 12-month price targets for Neurocrine Biosciences' shares. Their forecasts range from $90.00 to $149.00. On average, they anticipate Neurocrine Biosciences' share price to reach $126.53 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences or view Wall Street analyst' top-rated stocks.

Who are some of Neurocrine Biosciences' key competitors?

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of NBIX's competitors.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:

Dr. Kevin C. Gorman, CEO & Director (Age 63, Pay $1.45M)
Mr. Matthew C. Abernethy, Chief Financial Officer (Age 41, Pay $822.74k)
Dr. Haig P. Bozigian, Chief Devel. Officer (Age 63, Pay $780.63k)
Mr. Eric S. Benevich, Chief Commercial Officer (Age 56, Pay $793.07k)
Ms. Eiry Wyn Roberts, Chief Medical Officer (Age 57, Pay $899.55k)
Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 63)
Jane Sorensen, Head of Investor Relations
Mr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 55)
Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 48)
Ms. Julie Cooke, Chief HR Officer (Age 55)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.25%), State of Alaska Department of Revenue (0.05%), Polianta Ltd (0.01%), Red Spruce Capital LLC (0.01%), IFM Investors Pty Ltd (0.01%) and OneAscent Financial Services LLC (0.00%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, NuWave Investment Management LLC, Scout Investments Inc., Redpoint Investment Management Pty Ltd, and First Hawaiian Bank. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin.
View insider buying and selling activity for Neurocrine Biosciences or view top insider-selling stocks.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Vigilare Wealth Management, Polianta Ltd, IFM Investors Pty Ltd, OneAscent Financial Services LLC, Red Spruce Capital LLC, and Sowell Financial Services LLC.
View insider buying and selling activity for Neurocrine Biosciences or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $107.69.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.06 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 825 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here